Login / Signup

Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer.

Inae JeongJayoung SongSong Yi BaeSang-Kook Lee
Published in: Journal of cancer prevention (2019)
Based on these findings, AXL was found to be a promising therapeutic target to overcome the intrinsic resistance to gefitinib in NSCLC. Furthermore, YD is able to effectively regulate the expression of AXL and thus it may be applicable as a potential lead compound for the treatment of gefitinib-resistant NSCLC.
Keyphrases
  • small cell lung cancer
  • tyrosine kinase
  • epidermal growth factor receptor
  • advanced non small cell lung cancer
  • brain metastases
  • poor prognosis
  • cell proliferation
  • binding protein
  • human health
  • risk assessment